In this article
Cerebrolysin is a mixture of small protein fragments and amino acids made from pig brain tissue. It falls under the cognitive and neuroprotective research category. It is not FDA-approved in the United States.
Cerebrolysin
What it is
Cerebrolysin is not a single compound. It is a standardized mixture (made to the same recipe every time) of small protein fragments called neuropeptides and free amino acids. Neuropeptides are tiny proteins that carry signals in the brain and nervous system. Amino acids are the basic building blocks that make up all proteins. The mixture is made by using enzymes (think of them as natural molecular scissors) to break purified pig brain proteins into very small pieces. All of these pieces are small, generally below 10 kilodaltons in size. A kilodalton is a tiny unit used to measure how big a molecule is. Cerebrolysin is often called a neurotrophic or neuropeptide preparation, meaning it is studied for possible effects on brain cell health and signaling.
Research context and categorization
Investigational Scope
Cerebrolysin falls under the cognitive and neuroprotective research category. Neuroprotective means related to protecting nerve and brain cells. In published studies, it is discussed in connection with three areas: neuronal survival (keeping brain cells alive), neuroplasticity (the brain's ability to reorganize and adapt, like a road network rerouting around a closed road), and recovery of the central nervous system (the brain and spinal cord). It has been studied in connection with stroke recovery, traumatic brain injury, and several forms of dementia, including Alzheimer-related cognitive decline. It also appears in discussions of general cognitive support.
Clinical Evidence and Efficacy
From a U.S. regulatory standpoint, these uses are still investigational. That means they are still being studied and have not been confirmed. They should not be treated as proven benefits. The overall body of evidence is mixed.
Some dementia research trials have reported what looks like a benefit. However, a major stroke trial did not meet its primary endpoint (it did not reach the main goal it set out to achieve). In addition, systematic reviews (studies that pool and analyze results from many trials together) have rated much of the combined evidence as low quality and noted that certain results deserve closer examination.
In short, Cerebrolysin is still being studied and debated. The results described in the research literature remain unconfirmed and unapproved in the United States.
Key point: Cerebrolysin is an investigational agent with a mixed body of research evidence. It remains unapproved for medical use in the United States.
Status
- Regulatory status: Research-only in the United States. Cerebrolysin is not FDA-approved for any use. It is marketed and approved in roughly 50 other countries (mainly in Europe and Asia) for conditions such as stroke, traumatic brain injury, and dementia. However, that approval in other countries does not apply in the United States.
- Sport status: Not specifically listed on the WADA Prohibited List. (WADA stands for the World Anti-Doping Agency, which publishes a list of substances banned in sport.) Cerebrolysin does not appear as a named substance and is not identified as a prohibited peptide hormone or growth factor. Because the WADA Prohibited List is updated every year and includes broad language covering related substances, current status should be checked against the latest list before any competition context.
Reconstitution notes (general)
For a standard lyophilized (freeze-dried) research peptide, concentration equals the milligrams of compound in the vial divided by the millilitres of bacteriostatic water added. For example, 60 mg mixed with 2 mL of bacteriostatic water gives a concentration of 30 mg per mL.
A reconstitution calculator is available at peptide calculator. Note that this general powder formula does not describe how Cerebrolysin is typically supplied (see below).
Dilution and handling notes (compound-specific)
Supply and Workflow Exception
Cerebrolysin is an exception to the usual reconstitution workflow. It is generally supplied as a ready-to-use liquid in sealed glass ampoules (for example 2 mL, 5 mL, or 10 mL amber-colored glass ampoules), not as a freeze-dried powder that you mix with bacteriostatic water.
Because it already comes in liquid form, there is normally no reconstitution step. There is no powder to dissolve, and no issues with gelling, cloudiness, or particles forming on concentration, as can happen with some peptide powders.
Dilution and Storage Constraints
Where dilution is discussed in reference material, it applies only to larger volumes intended for slow infusion. In those cases, the ampoule solution is combined right before laboratory use with a compatible carrier such as:
- 0.9% sodium chloride (saline, a simple saltwater solution)
- 5% glucose solution (a simple sugar-water solution)
- Ringer's lactate (a balanced salt solution)
The solution should be used promptly after an ampoule is opened. Once opened, the ampoule is no longer sealed and sterile, and it is not meant for extended open storage.
One handling detail to note is that Cerebrolysin is a clear amber-tinted liquid. This means it looks different from a colorless reconstituted peptide, so the visual baseline for "something looks wrong" is different. Any diluted preparation is treated as single-use and is not stored after preparation.
Handling and storage
Temperature and Storage Guidelines
General cold-chain handling for this class of material means keeping it refrigerated at roughly 2 to 8 degrees Celsius, stored away from direct light, and protected from freezing.
Access and Quality Control
When accessing any vial or ampoule through a rubber stopper, wipe the stopper with an alcohol swab before access and label the container with the date it was opened or mixed.
Reconstituted or opened peptide solutions are commonly assigned a refrigerated working window of about four weeks. However, ready-to-use ampoule solutions like Cerebrolysin are typically single-use once opened.
Discard any solution that becomes cloudy, changes color beyond its normal appearance, or shows particles or floating material.
Related reading
Tools and supplies
- peptide calculator
- Bacteriostatic Water 30 ml
- Gansulin Metal Reusable Pen
- 3 ml Glass Cartridges (10-pack)
- Complete Starter Kit
Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.
Frequently asked questions
Is Cerebrolysin FDA-approved in the United States?
No. Cerebrolysin holds no FDA approval for any indication. It is approved in roughly 50 countries in Europe and Asia for stroke, TBI, and dementia, but those foreign approvals carry no U.S. regulatory standing.
What is Cerebrolysin made of?
It is a standardized mixture of small neuropeptides and free amino acids produced by enzymatic hydrolysis of purified porcine brain proteins; all resulting fragments are generally below 10 kilodaltons in molecular weight.
What does the clinical research evidence on Cerebrolysin show?
Evidence is mixed: some dementia trials report apparent benefit, but a major stroke trial did not meet its primary endpoint, and systematic reviews rate much of the pooled evidence as low quality, with certain results flagged for closer examination.
More in our reusable reconstitution pens collection.
What the research community gets wrong about Cerebrolysin
- Treating it like a single peptide. Cerebrolysin is a standardized mixture of many small peptide fragments and free amino acids, not one molecule. A single purity number or one molecular weight does not describe the whole vial, so batch and lot records matter more than a simple percent-pure label.
- Reaching for bacteriostatic water. It usually arrives as a ready-to-use liquid in sealed glass ampoules, not as a freeze-dried powder. There is normally no reconstitution step, so a mixing calculator and a bottle of bacteriostatic water are not part of this workflow.
- Assuming clear means colorless. The normal liquid is a clear amber tint. That color by itself is not a warning sign, so the visual baseline is different from a colorless reconstituted peptide. Cloudiness, particles, or floating material are still reasons to discard.
- Applying the four-week working window. Once an ampoule is opened it is no longer sealed or sterile. Ampoule solutions are typically single-use, unlike the roughly four-week refrigerated window some people assume for reconstituted powders.
- Reading foreign approval as settled science. Approval in other countries does not mean U.S. approval, and the published trial record is mixed. Some dementia trials report apparent benefit while a major stroke trial missed its main goal, and several reviews rate much of the pooled evidence as low quality.
From our bench: If you keep Cerebrolysin ampoules in cold storage, we would like your firsthand observations on appearance over time. Hold an unopened ampoule against a plain white background under steady light, note the amber tint and clarity, and record what you see at intake and again after several weeks of refrigerated storage. Tell us the storage temperature you logged, whether the tint or clarity shifted at all, and whether any particles or cloudiness appeared. Please share your own measured values, not estimates.
Sources
- Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
- Guekht et al., Pharmaceuticals (Basel) 2021 , Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials
- Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials, Cureus 2025 , Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke
- Rapid Health Technology Assessment, Medicine (Baltimore) 2024 , Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
